Drugs for Asthma and COPD Flashcards
1
Q
Albuterol
A
- SABA (Short Acting β2 Agonist): reverses the bronchoconstriction of asthma by relaxing airway smooth muscle
- risk of headache, dizziness, dry mouth, cough
2
Q
Terbutaline
A
- SABA (Short Acting β2 Agonist): reverses the bronchoconstriction of asthma by relaxing airway smooth muscle
- used for treatment or prophylaxis of bronchospasm associated with asthma
- only available as SubQ
- risk of headache, nausea, tachycardia, and palpitations.
3
Q
Metaproterenol
A
- SABA (Short Acting β2 Agonist): reverses the bronchoconstriction of asthma by relaxing airway smooth muscle
- used for bronchial asthma and for reversible bronchospasm
- risk of CV effects, paradoxical bronchospasm
4
Q
Pirbuterol
A
- SABA (Short Acting β2 Agonist): reverses the bronchoconstriction of asthma by relaxing airway smooth muscle
- used for reversal of bronchospasm in pts 12 years or older
- risk of CV effects on pulse or BP
5
Q
Levalbuterol
A
- SABA (Short Acting β2 Agonist): reverses the bronchoconstriction of asthma by relaxing airway smooth muscle
- Used in treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease.
6
Q
Beclomethasone
A
- Inhaled corticosteroid
- Used as maintenance treatment for asthma and as prophylactic therapy in patients 5 years of age and older
- reduce eosinophils in airway and sputum, and inhibit transcription of inflammatory proteins
- risk of adrenal dysfunction
7
Q
Budesonide
A
- Inhaled corticosteroid
- Used as maintenance treatment for asthma and as prophylactic therapy in patients 6 years of age and older
- reduce eosinophils in airway and sputum, and inhibit transcription of inflammatory proteins
- do NOT use as treatment for status asthmaticus, or severe episodes of asthma
8
Q
Ciclesonide
A
- Inhaled corticosteroid
- Used as maintenance treatment for asthma and as prophylactic therapy in patients 6 years of age and older
- reduce eosinophils in airway and sputum, and inhibit transcription of inflammatory proteins
- do NOT use for relief of acute bronchospasm
- less likely to cause candidiasis
9
Q
Flunisolide
A
- Inhaled corticosteroid
- Used as maintenance treatment for asthma and as prophylactic therapy in patients 6 years of age and older
- may replace oral CS
- reduce eosinophils in airway and sputum, and inhibit transcription of inflammatory proteins
- do NOT use as treatment for status asthmaticus, or severe episodes of asthma
10
Q
Fluticasone
A
- Inhaled corticosteroid
- Used as maintenance treatment for asthma and as prophylactic therapy in patients 4 years of age and older
- reduce eosinophils in airway and sputum, and inhibit transcription of inflammatory proteins
- risk or oral candidiasis
11
Q
Mometasone
A
- Inhaled corticosteroid
- Used as maintenance treatment for asthma and as prophylactic therapy in patients 4 years of age and older
- reduce eosinophils in airway and sputum, and inhibit transcription of inflammatory proteins
- do NOT use in pts with sensitivity to milk proteins, as treatment for status asthmaticus, or severe episodes of asthma
12
Q
Triamcinolone
A
- Inhaled corticosteroid
- Used as maintenance treatment for asthma and as prophylactic therapy
- reduce eosinophils in airway and sputum, and inhibit transcription of inflammatory proteins
- May replace Oral CS
- do NOT use as treatment for status asthmaticus, or severe episodes of asthma
- risk of adrenal dysfunction
13
Q
Prednisone
A
- Oral Corticosteroid
- Used as an anti-inflammatory or immunosuppressive agent and in endocrine conditions
- May lead to hypothalamic-pituitary-adrenal (HPA) axis suppression
14
Q
Fomoterol
A
- LABA (Long Acting β2 Agonist)
- Treatment of asthma in patients ≥5 years as an ADD-ON to a long-term asthma control medication such as an inhaled corticosteroid.
- Maintenance treatment of bronchoconstriction in patients with COPD
- risk of asthma-related deaths and asthma-related hospitalizations.
15
Q
Salmeterol
A
- LABA (Long Acting β2 Agonist)
- Treatment of asthma in patients aged 4 years and older. Prevention of exercise-induced bronchospasm (EIB) in patients aged 4 years and older.
- Also, maintenance treatment of bronchospasm associated with COPD
16
Q
Indacaterol and Vilanterol
A
- LABA (Long Acting β2 Agonist)
- Used to treat breathing problems caused by COPD
17
Q
Olodaterol
A
- LABA (Long Acting β2 Agonist)
- Used in the long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with COPD
18
Q
Atropine
A
- Muscarinic receptor antagonist
- When the recurrent use of atropine is essential in patients with coronary artery disease, the total dose should be restricted to 2 to 3 mg to avoid the detrimental effects of atropine-induced tachycardia on myocardial oxygen demand.
19
Q
Ipratroprium
A
- Muscarinic receptor antagonist
- Used as a bronchodilator for maintenance treatment of bronchospasm associated w/ COPD
- poorly absorbed after aerosol administration and is therefore relatively free of systemic atropine-like effects.
20
Q
Tiotropium
A
- Muscarinic receptor antagonist
- maintenance treatment of bronchospasm associated with COPD
21
Q
Aclidinium
A
- Muscarinic receptor antagonist
- maintenance treatment of bronchospasm associated with COPD
22
Q
Theophylline
A
- Methylxanthine
- Smooth muscle relaxation (bronchodilation) and suppression of the response of the airways to stimuli
23
Q
Montelukast
A
- Leukotriene Receptor (CysLT1) Antagonist
- treat allergies and prevent asthma attacks.
- NOT indicated for use in the reversal of bronchospasm in acute asthma attacks, including status asthmaticus.
24
Q
Zafirlukast
A
- Leukotriene Receptor (CysLT1) Antagonist
- Selective and competitive receptor antagonist of leukotriene D4 and E4
- Prescribed for the prophylaxis and chronic treatment of asthma in adults and children 5 years of age and older
- risk of hepatotoxicity
25
Q
Zileuton
A
- Inhibitor of 5-lipoxygenase and thus inhibits leukotriene
- Used as a prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older and not used to treat an acute asthma attack.
- Do not use in active liver dz
26
Q
Omalizumab
A
- anti-IgE antibody
- used for moderate to severe persistent asthma in patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids.
- also used for chronic idiopathic urticaria
- risk of anaphylaxis